Effect of NT-proBNP Guided Treatment of Chronic Heart Failure

Netherlands Heart Foundation

Status: Completed

Conditions: Heart Failure, Congestive

Treatments: Device: NT-proBNP measurements

Study type: Interventional

Funder types: Other

Identifiers

NCT00149422

2003B131

Details and patient eligibility

About

The purpose of this study is to determine whether NT-proBNP guided treatment of chronic congestive heart failure will reduce heart failure related morbidity and mortality compared to therapy guided by standard clinical judgement.

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Admission because of congestive heart failure
• Elevated NT-proBNP levels on admission

Exclusion criteria

• Life-threatening cardiac arrhythmias
• Urgent intervention
• Severe lung disease
• Presence of life threatening disease
• Signed informed consent for other study
• Mental or physical status not allowing written informed consent.
• Unwillingness to give informed consent
• Patients undergoing haemodialysis or continuous ambulatory peritoneal dialysis (CAPD)

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

0 participants in 2 patient groups, including a placebo group

NT-proBNP guided treatment group

Active Comparator group

Description:

In this group, management was guided by an individually set NT-proBNP, defined by the lowest level at discharge or 2 weeks thereafter. If NT-proBNP levels were elevated above the individually set NT-proBNP interventions were performed according to the ESC heart failure guidelines.

Treatment:

Device: NT-proBNP measurements

Clinically guided arm

Placebo Comparator group

Description:

Heart failure treatment guided by clinical assessment.

Treatment:

Device: NT-proBNP measurements